Outlook Therapeutics, Inc. (OTLK)
2025-06-30 | ||||
|---|---|---|---|---|
| Revenues, net | 1,505,322 | |||
| Cost of revenues | 439,815 | |||
| Gross profit | 1,065,507 | |||
| Research and development | 7,134,706 | |||
| Selling, general and administrative | 9,679,481 | |||
| Loss from operations | -15,748,680 | |||
| Interest expense (income), net | -49,351 | |||
| Loss on equity method investment | -30,884 | |||
| Gain from change in fair value of warrant liability | 1,999,610 | |||
| Loss from change in fair value of promissory notes | 2,323,977 | |||
| (loss) income before income taxes | -20,152,502 | |||
| Net (loss) income | -20,152,502 | |||
| Earnings per share, basic | -0.55 | |||
| Earnings per share, diluted | -0.55 | |||
| Weighted average number of shares outstanding, basic | 36,956,582 | |||
| Weighted average number of shares outstanding, diluted | 36,956,582 | |||